glp-1 receptor agonist manufacturers Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 glp 1 companies list North

Description

22 Long-term safety data remain limited, warranting cautious consumption pending comprehensive toxicological studies

It wins decisively, and for many people this single factor determines the entire decision

SAA supervised the project

By Lana Pine | Published on June 19, 2025 4 min read People with diabetes who take glucagon-like peptide-1 (GLP-1) receptor agonists (such as Ozempic and Wegovy) may have more than twice the risk of developing a serious eye condition called neovascular age-related macular degeneration (nAMD) a leading cause of vision loss in older adults according to a large-scale study published in JAMA Ophthalmology